United Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Rating of "Moderate Buy" from Brokerages

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen brokerages that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $383.08.

A number of research analysts have issued reports on UTHR shares. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. UBS Group reduced their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. Morgan Stanley dropped their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd.

Insider Activity

In related news, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. This trade represents a 11.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,681 shares of company stock worth $22,140,089. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the first quarter worth $32,000. Dunhill Financial LLC lifted its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares in the last quarter. Geneos Wealth Management Inc. raised its position in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Sound Income Strategies LLC purchased a new stake in United Therapeutics during the first quarter valued at approximately $49,000. Finally, Brooklyn Investment Group grew its stake in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $297.33 on Friday. The company has a market capitalization of $13.41 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 6.52 and a beta of 0.53. The business has a fifty day moving average price of $300.61 and a two-hundred day moving average price of $318.55. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.17 EPS. Sell-side analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.